Camlin Fine Sciences growth ratios

·ChemicalsChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY22 and earlierAlpha Plus
+3.4%+3.3%−4.1%
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
−48.6%+181.6%−64.0%
−75.1%+3,175.5%−103.3%
+114.9%−50.8%−363.4%
+118.2%−43.9%−261.7%
+14.8%+3.7%−5.3%
+14.4%+2.1%+4.0%
+207.1%−80.8%+173.1%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

CAMLINFINE₹82.32

Camlin Fine Sciences Limited

· Chemicals
₹ CrorePeersCLEANDEEPAKNTRBAYERCROPTIRUMALCHMATULSHKPAUSHAKLTDANURASMcap ₹1,581 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue Growth—-4.1+3.3+3.4—
EBITDA Growth—-64.0+181.6-48.6—
EBIT Growth—-103.3+3,175.5-75.1—
Net Income Growth—-363.4-50.8+114.9—
EPS Growth—-261.7-43.9+118.2—
Total Assets Growth—-5.3+3.7+14.8—
Total Equity Growth—+4.0+2.1+14.4—
Cash from Operations Growth—+173.1-80.8+207.1—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.